SRx closes second $3.5M tranche, nearing $8M Series B cap
What's the deal? SRX Global (NYSE American: SRXH), formerly SRx Health Solutions, closed a second tranche of its Series B private placement on July 27, 2026, raising $3.472 million in cash. It issued 4,340 shares of Series B convertible preferred stock and 284,156 warrants to accredited investors.
Why now? The raise is a quick re-raise: it is the second closing under a Securities Purchase Agreement signed on March 16, 2026. The company has now taken in roughly $7.9 million of the $8.0 million maximum authorised under that agreement.
What's the mechanism? The agreement allows for up to 10,000 Series B preferred shares plus accompanying warrants. All securities were issued unregistered under Section 4(a)(2) and Regulation D exemptions, meaning resale is restricted absent registration.
What could go wrong? The placement dilutes existing shareholders through both the preferred stock and the warrants, which add further dilution on exercise. The company also completed a 60-for-1 reverse stock split effective July 2, 2026, weeks before this closing.
The signal: With nearly 99% of the $8.0 million cap accessed and one potential closing left, SRx is drawing down its authorised private placement quickly — a sign of ongoing funding needs as the North Palm Beach, Florida-based company works through its capital raise.
Read more: Top Penny Stocks Watch
